This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
Participant must be aged greater than equal to (>=)18 years at the time of signing the informed consent.
Documented history of asthma, as defined by Global Initiative for Asthma (GINA)
Short-Acting beta2-Adrenoreceptor Agonists (SABA) as needed (prn) only
Inhaled corticosteroid (ICS)/SABA prn only
Participants with a history of life-threatening asthma.
Participants with other significant pulmonary diseases, including (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis, or other significant respiratory abnormalities other than asthma.
Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening.
Participants with severe asthma exacerbation: Defined as any asthma exacerbation requiring >=3 days systemic corticosteroids or that resulted in overnight hospitalization or Emergency Department visit requiring additional treatment for asthma within the 3 months prior to screening.
Crossover
HFA-152a
DrugHFA-152a will be administered.
HFA-134a
DrugHFA-134a will be administered.
Number of participants with adverse events (AEs)
Number of participants with serious adverse events (SAEs)
Absolute values for vital sign parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (Millimeters of mercury [mmHg])
Absolute values for vital sign parameter: Pulse rate
Change from Baseline in vital sign parameters: SBP and DBP (mmHg)
Click on the lead sponsor to view all of their trials.
